Background-The involvement of the complement system in brain injury has been scarcely investigated. Here, we document the pivotal role of mannose-binding lectin (MBL), one of the recognition molecules of the lectin complement pathway, in brain ischemic injury. Methods and Results-Focal cerebral ischemia was induced in mice (by permanent or transient middle cerebral artery occlusion) and rats (by 3-vessel occlusion). We first observed that MBL is deposited on ischemic vessels up to 48 hours after injury and that functional MBL/MBL-associated serine protease 2 complexes are increased. Next, we demonstrated that (1) MBL Ϫ/Ϫ mice are protected from both transient and permanent ischemic injury;
S troke is a leading cause of death and permanent disability worldwide. Despite recent substantial progress in prevention and management, stroke still remains a large unmet medical need. Ischemic stroke, that includes 87% of all strokes and is caused by thrombotic or embolic occlusions, occurs when the blood supply to part of the brain is restricted, leading to energy deficit. In areas with the lowest residual flow, cells die rapidly, whereas in areas with less severe ischemia that surround the lesion core, cells may remain viable for hours to days and represent possible therapeutic targets. 1 Presently, the only treatment available for stroke is thrombolysis with tissue plasminogen activator. The narrow 3-hour therapeutic window imposed by safety concerns (only recently extended to 4.5 hours 2 ) allows Ͻ5% of patients to be eligible for tissue plasminogen activator treatment. 3, 4 Thus, the inadequacy of available therapeutic strategies demands the identification of novel ameliorative treatments endowed with a wide therapeutic window.
Clinical Perspective on p 1494
Several pathogenetic mechanisms contribute to ischemic injury. Among them, the inflammatory response, after being rapidly triggered, progresses over hours to days, making it an attractive target for therapeutic intervention. The complement system is a powerful arm of inflammation. It becomes rapidly activated after injury and acts as a trigger for several aspects of the inflammatory response. Complement is a proteolytic cascade of several circulating and cell-associated proteins that contribute to the evolution of injury by several potential mechanisms, including inflammatory molecule synthesis, recruitment of cells to the site of injury, activation of phagocytosis, induction of endothelial damage and increased vascular permeability, and by directly inducing cell death. Depending on the trigger, complement activation may proceed through 3 separate pathways, namely, the classical, lectin, and alternative pathways. 5 Both animal models and clinical observations indicate that the complement system is one of the mechanisms contributing to ischemic injury. 6 -8 C1-INH, an endogenous inhibitor of the complement system endowed with several anti-inflammatory effects, acts as a potent neuroprotective agent against acute brain injury. 9 -13 We showed previously that recombinant C1-INH markedly reduced cerebral damage when administered up to 18 hours after ischemia in mice. 12 Our data further suggested that the remarkable protective action was due to its binding to mannose-binding lectin (MBL), one of the recognition molecules responsible for the first step of complement activation of the lectin pathway. 14 MBL is a serum protein that acts as a circulating pattern recognition receptor. MBL targets include pathogen-associated molecular patterns, ie, carbohydrates exposed on the surface of a pathogen but also "altered self" or damage-associated molecular patterns, ie, dying or damaged cells through recognition of changes in glycosylation pattern on the cell surface. The binding of MBL to its targets leads to complement activation. 14 Our previous data prompted us to hypothesize that MBL plays a pathogenetic role in the ischemic injury and that compounds that bind and inhibit MBL may represent a promising therapeutic modality for stroke. Here, we document the pivotal role of MBL in cerebral ischemic injury by using different experimental models of focal ischemia. Because the degree of reperfusion is variable in the clinical setting, 1, 15 we used both transient and permanent middle cerebral artery occlusion (tMCAo and pMCAo, respectively) in mice. 9, 10, 12 In addition, an inhibitory monoclonal antibody against rat MBL-A 16 was also used in a reversible 3-vessel occlusion model (3-vo) in rats. 17
Methods

Animals
Male C57Bl/6 (26 -28 g, Harlan, Italy, and Taconic Farms for the complement hemolytic assay) and C57Bl/6 with target mutation of both MBL-A and MBL-C genes (MBL Ϫ/Ϫ , 26 -28 g, Jackson Laboratories,) mice, and Crl:CD (SD)BR (250 -280 g, 7-8 weeks, Charles River, Calco, Italy) rats were used. Additional information in online-only Data Supplement Methods.
Drugs
Anti-rat MBL-A monoclonal antibodies (clones P2D5 and 14C, 1 mg/kg) were diluted in phosphate-buffered saline and injected intravenously. 16, 18 Polyman2 was dissolved in phosphate-buffered saline at a concentration of 450 (or 900) M. One hundred microliters of this solution were injected intravenously to obtain circulating levels corresponding to 30 (or 60) M, corresponding to 142 (or 284) g per mouse, which represented the best binding concentration to MBL in surface plasmon resonance (SPR) experiments. Additional information on Polyman2 toxicity is in online-only Data Supplement Methods.
Focal Ischemia in Mice: tMCAo and pMCAo
Surgery
Transient ischemia was achieved by tMCAo by means of a siliconized filament (7-0, Doccol Corporation) introduced into the internal carotid artery and advanced to block the MCA for 30 minutes as described previously. 9, 10, 19 The surgery-associated mortality rate was 8%. For permanent ischemia (pMCAo), the MCA was permanently occluded by electrocoagulation. 20, 21 The mortality rate for this model was 8.5%. In both ischemia models, sham-operated (sham) mice received identical anesthesia and surgery without artery occlusion.
Neurological Deficits
Forty-eight hours after tMCAo, each mouse was rated on neurological function scales unique to the mouse. Scores range from 0 (healthy) to 56 (the worst performance in all categories) and represent the sum of the results of general and focal deficits (13 categories) . Results are expressed as a composite neurological score.
Quantification of Infarct Size and Edema
Infarct volumes were calculated on 20-m coronal brain cryosections stained with cresyl violet by the integration of infarcted areas after correction for the percentage of brain swelling due to edema. Edema was determined by subtracting the area of the ipsilateral from that of the contralateral hemisphere.
Additional information on surgery, neurological deficits, and quantification of infarct size and edema is in online-only Data Supplement Methods.
Focal Ischemia in Rats: 3-vo
Surgery was performed as described previously. 17, 22 The right common carotid artery and the MCA were occluded. Subsequently, to produce a lesion in the MCA region, the contralateral common carotid artery was occluded for 1 hour by the use of traction with fine forceps. This procedure induces a blood flow drop in the MCA territory. Reperfusion was induced by forceps release. Sham rats were operated on in the same way, but the MCA and common carotid arteries were not occluded. The surgery-associated mortality rate was 7%.
Neurological Deficits
Postural reflex was assessed by the Bederson test, sensorimotor integration by the De Ryck limb-placing test, and the ability to integrate motor responses by the foot-fault test as previously described. 17
Quantification of Infarct Size
Injury was quantified on 14 serial 1-mm thick sections stained with triphenyltetrazolium chloride (Sigma-Aldrich). 17 Alternatively, 4 weeks after ischemia, ischemic volume was evaluated by structural MRI analysis (see below).
Additional information on surgery, neurological deficits, and quantification of infarct size is in online-only Data Supplement Methods.
MRI Measurements
Imaging was performed on a 7T small-bore animal Scanner (Bruker Biospec). The morphological images were obtained with a RARE T2-weighted sequence that covered the whole rat brain volume.
Volumetric Measurements
The volume measurements of structural MRI images were obtained manually by using custom-made software as previously described. 23 For each animal, the regions of interest were manually chosen and drawn on the images for volumetric assessments. We computed the lesion volume including the whole infarcted tissue (T2w hyperintense tissue indicative of edema 24 ) across different brain areas. This measurement did not include the ventricle volume. Measurements of brain atrophy in cortex, hippocampus, and striatum 25 included residual T2w hypointense tissue. Data from each animal were obtained by the integration of averaged region of interest area for slice thickness. Additional information is in online-only Data Supplement Methods.
Immunofluorescence and Confocal Analysis
Twenty-micrometer-thick coronal sections were incubated with the primary monoclonal antibodies anti-mouse MBL-A or MBL-C (1:100; Hycult Biotechnology). Alexa546 fluoro-conjugated goatanti-rat IgG (1:500; Molecular Probes) was used as a secondary antibody. Brain vessels and nuclei were stained with Alexa488 fluoro-conjugated isolectin (IB4, 1:200; Invitrogen) and 4Ј-6diamidino-2-phenylindole (1 g/mL; Invitrogen), respectively. Images were acquired by confocal microscopy as described previously. 21 Three-dimensional images were acquired over a 10-to 12-m z axis with a 0.23-m step size and processed by using Imaris software (Bitplane) and Photoshop CS2 (Adobe Systems Europe Ltd).
Semiquantitative evaluation of MBL deposition on blood vessels was performed at each time point. 12 Additional information is in online-only Data Supplement Methods.
Functional MBL/MBL-Associated Serine Protease 2 Assay
Blood samples were collected from the vena cava in 10 mmol/L EDTA and 0.125% polybrene (Sigma-Aldrich). Functional MBL/ MBL-associated serine protease 2 (MASP-2) complexes were measured in plasma by ELISA (Hycult Biotechnology). 12
Western Blot
Equal amounts of plasma proteins (10 g per sample) were electrophoresed on a 5% sodium dodecyl sulfate polyacrylamide gel and transferred to polyvinylidene fluoride membranes. Rabbit anti-C3 polyclonal antibody (1:100) followed by rabbit peroxidaseconjugated antibody (1:2500; both Santa Cruz Biotechnology) were used. Results were standardized by using the total protein loaded. Additional information is in online-only Data Supplement Methods.
Surface Plasmon Resonance
SPR binding studies were performed by using the ProteOn XPR36 system (Bio-Rad), as previously described. 12 In brief, polymannosylated dendrimers were flowed onto recombinant human MBL covalently immobilized on the sensor chip. The resulting sensorgrams were fitted by the simplest 1:1 interaction model to obtain the binding constants. Additional information is in online-only Data Supplement Methods.
Complement Hemolytic Assay
Mice were divided in the following groups (nϭ3/group): (1) wild typeϩsaline (vehicle control) and (2) wild typeϩPolyman2. Under isoflurane anesthesia, 50 L of normal saline (control) or 50 L of saline containing 142 g of Polyman2 was injected intravenously. After 1 hour, blood was collected via heparinized syringes and serum prepared. The CH50 assay was performed as we have previously described, but with modifications. 26 Additional information in online-only Data Supplement Methods.
Blinding and Exclusion Criteria
In each and every experiment, animals (including C57Bl/6 and MBL Ϫ/Ϫ mice and Crl:CD(SD)BR rats) were allocated at random to surgery and treatment group, taking care to distribute them equally across experimental days and batches to avoid systematic errors. All the experimental procedures including surgery, drug treatment, behavioral tests, immunohistochemistry, quantification of infarct size, MRI analysis, and biochemical assays were performed by investigators blinded to the experimental conditions. Animals, in which the intravenous administration of drug or vehicle was not successful, were excluded from the study (mice: 13/86 and rats: 2/77).
Statistics
Data are expressed as meanϩSD or as scatter-dot plots and mean (bars). GraphPad Prism 5 software was used for statistical analysis. All of the data have been checked for normal distribution by the Kolmogorov-Smirnov test and for the constancy of variances by the Bartlett test, in case of Ͼ2 groups, or by F test, in case of 2 groups. The Kruskal-Wallis test was used when data were not distributed normally. The t test with the Welch correction was used for normally distributed data with unequal variances. Additional information on the tests used are reported in the figure legends and in online-only Data Supplement Methods.
Results
The Lectin Pathway in Brain Ischemia
We first investigated whether MBL could be detected in the ischemic brain. We assessed the presence of MBL-A and MBL-C, the 2 isoforms present in mice, 27 at 30 minutes and at 6, 12, 24, and 48 hours following tMCAo or pMCAo ( Figure 1 ). MBL was detected in tMCAo mice starting from 6 hours and in pMCAo mice from 30 minutes. In both models, the strongest signal was observed at 12 to 24 hours and persisted up to 48 hours after ischemia ( Figure 1E We next assessed the presence of circulating MBL/ MASP-2 functional complexes, as an index of lectin pathway activation. We previously demonstrated that tMCAo induced a significant increase in MBL/MASP-2 complexes in comparison with sham-operated mice. 12 In the present study, we found that both 30 minutes and 24 hours after pMCAo, ischemic mice had a significant increase (up to 26.6% and 31.9%, respectively) in circulating functional MBL/MASP-2 complexes in comparison with sham-operated mice ( Figure  2A and 2B), indicating an early and persistent activation of the lectin complement pathway following pMCAo. Notably, 24 hours after pMCAo, ischemic mice had a significant increase in circulating C3 fragments in comparison with sham-operated mice (up to 64.5%; Figure 2C ), indicating a long-lasting activation of the complement system.
Susceptibility of MBL ؊/؊ Mice to MCAo Injury
To further establish the relevance of MBL after ischemic injury, we then assessed the susceptibility of MBL Ϫ/Ϫ mice to ischemia. First, we assessed cerebral blood flow perfusion rates by laser Doppler flowmetry (Perimed Italy) and found that in MBL Ϫ/Ϫ they were not different from wild-type mice (online-only Data Supplement Figure II) . Similarly to what was observed after tMCAo (online-only Data Supplement Figure II) , 28, 29 MBL Ϫ/Ϫ mice subjected to pMCAo had smaller lesions in comparison with wildtype mice, corresponding to a 48% decrease of infarct volume ( Figure 2D ).
SPR Analysis of Mannosylated Molecules
We then sought to identify a synthetic MBL ligand directed against the mannose recognition binding site (carbohydrate recognition domain, CRD) to be used as a possible Figure III) . These studies highlighted the importance of both the number of pseudomannosides present on the dendrimeric scaffold (online-only Data Supplement Figure 3 ) and the structure of the scaffold (eg, Polyman2 versus Polyman17 in Figure 3A ), and indicated Polyman2 as the best MBL ligand, with an affinity of 6 mol/L ( Figure 3B ). 
Effect of the Mannosylated Molecule Polyman2 in MCAo Injury
Polyman2 was therefore selected for the in vivo studies and administered intravenously to tMCAo mice, at doses that reached plasma concentrations of 30 or 60 mol/L (142 or 284 g per mouse, respectively) to mimic the concentrations that were functionally active in SPR experiments. Both doses, given at reperfusion (30 minutes from the beginning of ischemia), induced a marked reduction in ischemic volume by 33.2% and 34.2% in comparison with vehicle-treated mice (online-only Data Supplement Figure IV) . Thus, all subsequent experiments were performed by using 30 mol/L Polyman2.
First, we demonstrated that Polyman2 did not induce complement depletion in vivo. Plasma from vehicle-or Polyman2-treated mice restored C5 activity to human C5depleted sera to the same extent over a wide range of plasma concentrations ( Figure 4A ). Next, to explore the therapeutic window against ischemic injury, Polyman2 or vehicle was infused intravenously once at different time points following tMCAo (3, 6, 12, 18, 24, or 30 hours from the beginning of ischemia). Neurological deficits, determined 48 hours after tMCAo, indicated that Polyman2 significantly reduced ischemic functional deficits when given up to 30 hours after the ischemic insult in comparison with vehicle-treated mice ( Figure 4B ) and reduced the ischemic volume by 46.4% when given 24 hours after ischemia ( Figure 4C ). Notably, in the absence of any treatment, the ischemic lesion increases by 55% from 24 to 48 hours (36.8Ϯ13.2 versus 56.2Ϯ16.2, nϭ12). The strongest protective effect (68.3% reduction) was observed when Polyman2 was given 6 hours following tMCAo ( Figure 4C ). At this time point, the maximal effect of Polyman2 on reduction of brain edema was also observed (online-only Data Supplement Figure V) .
In Polyman2-treated mice, the ischemia-induced MBL deposition on brain endothelium was effectively dampened at 24 hours ( Figure 4D ), and circulating C3 fragments were decreased 48 hours after injury ( Figure 4E and 4F ). Importantly, Polyman2 given 6 hours after injury to MBL Ϫ/Ϫ mice was not able to affect either the functional or the anatomic damage, showing the specificity of the protective effect ( Figure 4G and 4H) .
Mice receiving Polyman2 treatment 3 or 6 hours after pMCAo did not show a significant decrease of the lesion size nor reduction of MBL deposition or of C3 fragmentation (online-only Data Supplement Figure VI) .
Effect of the Anti-MBL-A Antibody Administration
Because no functionally inhibitory antibody against mouse MBL is available, we then assessed the effect of an anti-MBL monoclonal antibody directed against rat MBL-A (mAb P2D5 clone 16 ), the most abundant MBL isoform in rats. 27 P2D5 has potent neutralizing properties against MBL-A but does not recognize MBL-C. 16 This clone (1 mg/kg 16 ) or the vehicle was administered intravenously 20 minutes before ischemia or 6, 18, or 24 hours in rats subjected to reversible 3-vo. 22 Neurological deficits and ischemic volume were determined 48 hours after injury. Both postural-reflex deficits (the Bederson test; Figure 5A ) and sensorimotor deficits (the De Ryck test; Figure 5B ) were significantly improved in all mAb-treated rats, even those receiving the antibody 18 hours after injury. The ability to integrate motor responses (footfault test; Figure 5C ) was also improved in rats treated up to 18 hours after injury, but it did not reach statistical significance. Evaluation of anatomic injury demonstrated that rats treated with the mAb up to 18 hours after ischemia had a significant reduction in ischemic volume (posttreatment at 18 hours: 19% reduction; Figure 5D ).
We also assessed the specificity of the protective effect elicited by P2D5 by administering mAb 14C that binds rat MBL-A but is not functionally inhibitory 18 (isotype control antibody; Figure 5E ). When injected 18 hours after 3-vo, mAb 14C did not ameliorate any of the functional deficits or anatomic damage in comparison with vehicle-treated rats ( Figure 5E ).
In a subsequent experiment, rats were treated with P2D5 (1 mg/kg) 18 hours after ischemia and were analyzed serially out to 28 days to assess whether the antibody's protective effect was long lasting. Postural and sensorimotor deficits and the ability to integrate motor responses were significantly improved in mAb-treated rats up to 28 days ( Figure 6A through 6C). Because it is not practical to assess classical histological injury at this late time point, we analyzed the ischemic rat brains by MRI, evaluating the extension of the lesion and tissue atrophy. We found that antibody-treated rats had a significant reduction in the overall ischemic volume (58.2%; Figure 6E ), and less atrophy in the hippocampus ( Figure 6F ) and cortex ( Figure 6G ), as well, but not in striatum (not shown) in comparison with vehicle-treated rats.
Discussion
This study establishes a pivotal role for MBL in the pathogenesis of brain ischemic injury and demonstrates in multiple models and with the use of 2 structurally different inhibitors that MBL's inhibition leads to protection with a surprisingly wide therapeutic window. We have shown that MBL is deposited on the ischemic endothelium after injury (with and without reperfusion) and that functional MBL/MASP-2 complexes are increased following pMCAo similarly to what is observed after tMCAo, 12 indicating lectin pathway activation by the ischemic injury. Furthermore, by using 3 independent lines of evidence, we demonstrated that MBL inhibition is protective by observing the following: (1) the susceptibility of MBL Ϫ/Ϫ mice to tMCAo and pMCAo is decreased in comparison with wild-type mice; (2) Polyman2, a new dendrimeric molecule binding MBL with high affinity, induces a significant reduction of neurological deficits and ischemic volume when given up to 24 hours after injury induction; and (3) the anti-MBL mAb induces a significant and long-lasting reduction of neurological deficits and ischemic volume when given up to 18 hours after the induction of ischemic injury in rats.
The most relevant finding of this study is the surprisingly wide therapeutic window that can be obtained by administering either Polyman2 or the anti-MBL mAb. Interestingly, in 2 different models of ischemia /reperfusion injury (tMCAo in mice and 3-vo in rats), the extent of the protection and the effective therapeutic window were very similar. We do not know if the deposition of MBL on the ischemic vessels has a direct pathogenetic effect, but the observation that it decreases in tMCAo mice treated with Polyman2 (and not in pMCAo mice in which Polyman2 is not effective) suggests that this may be the case. Thus, the intraluminal deposition of MBL may be the important event implying that the drugs (Polyman2 or the antibody) do not need to cross the blood brain barrier to be effective.
Notably, MBL deposition is triggered early after ischemia and lasts up to 48 hours. Thus, we hypothesize that the wide therapeutic window may be a result of targeting such a long-lasting event.
Recent data implicate MBL and/or the lectin pathway in reperfusion injury in several organs. [31] [32] [33] [34] [35] [36] Here, we demon- strate that MBL Ϫ/Ϫ mice are protected even in the absence of reperfusion. MBL Ϫ/Ϫ mice subjected to pMCAo show a dramatic reduction of the lesion volume in comparison with wild-type mice. Similar to observations in tMCAo (present results and references 28, 29 ), pMCAo mice deposit MBL on ischemic vessels, increase levels of functional MBL/MASP-2 complexes, and increase circulating C3 fragments, thus implicating that activation of the lectin pathway following brain ischemia does not need reperfusion. However, Polyman2 was ineffective in reducing the ischemic lesion when administered to pMCAo mice, possibly because of its inability to reach the vessels in the ischemic area owing to the permanent vessel occlusion. Alternatively, we cannot exclude that higher doses could be needed for Polyman2 to reach the areas where MBL is deposited on the ischemic endothelium following pMCAo. However, because, in the clinical setting, areas lacking reperfusion are mingled with reperfused areas, 1,15 this limitation would not, in principle, prevent a possible efficacy in human stroke.
MBL circulates in complexes with serine proteases (MASPs) and other nonenzymatic proteins. 37 On MBL binding to its carbohydrate target, MASPs are activated and cleave C4 and C2 to form the C3 convertase, which may lead to activation of the entire complement system (eg, through to formation of C5b-9). Circulating MBL recognizes highly mannosylated glycoproteins expressed on the surface of pathogens or of altered self-cells through its C-terminal CRD. 14, 38 Functional assembly into oligomeric structures allows formation of multiple CRD domains (clusters of 2-6 CRDs), which leads to an efficient binding complex with multivalent properties. Although the binding affinity of each individual interaction between the CRD and the mannosylated glycoproteins is relatively low, the selfassembly into high-order oligomers provides a way for MBL to recognize repetitive arrays of its carbohydrate targets with high avidity. Thus, to effectively interfere with these multivalent interactions, multivalent inhibitors have to be designed. Polyman2 (previously referred to as Dendron 12 30 ) is a tetravalent pseudotrimannoside dendron. It is formed by a tetravalent polyester scaffold, decorated with a mimic of linear 1,2-to 1,6-trimannoside. Polyman2 was selected as the most active MBL-binding complex by SPR analysis from a small group of congeners that varied in structure of the dendron scaffold and the nature of the mannose-based ligand. Polyman2 has a high solubility in physiological media, negligible cytotoxicity, and a stability of 6 to 12 hours at pH 7.4 in aqueous solution. 30 In vivo, on administration to Ϸ60 ischemic Figure VIIB) or mAb 20 minutes before, or 6, 18, 24 hours (nϭ10, 6, 6, and 6, respectively) after 3-vo: postural-reflex deficit (A, Bederson test, normal scoreϭ5); sensorimotor deficit (B, De Ryck test, normal scoreϭ16); integration of motor responses (C, foot-fault test, normal scoreϭ2); anatomic damage (D, infarct volume). The administration of an isotype control mAb (clone 14C, 1 mg/kg IV) did not affect any of these parameters (E, nϭ10 -11 per group). Data are expressed as meanϩSD. Kruskal-Wallis test followed by the Dunn test (A through C), one-way ANOVA followed by Dunnett post hoc test (D) and unpaired t test (E); *PϽ0.05, **PϽ0.01, ***PϽ0.001 versus vehicle. mAb indicates monoclonal antibody; MBL, mannose-binding lectin; and 3-vo, 3-vessel occlusion model. mice we could not detect any apparent sign of toxicity. Importantly, Polyman2 does not activate and deplete complement.
Because of the presence in vivo of several structures potentially capable of recognizing mannosides, 39 Poly-man2 could also act on other CRD targets. The inability to exert an additional protective action in MBL Ϫ/Ϫ mice suggests that the protective effect of Polyman2 involves its interaction with MBL.
MBL is widely known as the first step of activation of the lectin complement pathway. We cannot exclude that MBL may have a direct toxic effect, independent from its ability to activate complement. Recent data obtained in a renal ischemia injury model show that MBL-mediated tubular injury is independent of complement activation and that MBL-mediated cell death precedes complement activation. 40 Thus, future studies are needed to fully elucidate this aspect in brain injury.
In humans, MBL is encoded by a single gene, whereas in rodents it is encoded by 2 different genes, MBL-A and MBL-C. Both rodent MBLs form higher oligomeric structures and activate complement. They display slightly different ligand specificities and may be differently expressed in different tissues; however, whether they also possess other common or divergent biological functions is not known yet. 27,41 Figure 6 . Anti-MBL-A antibody protection form ischemic injury is long lasting. Anti-MBL-A mAb (P2D5 clone, 1 mg/kg IV) was given 18 hours after 3-vo (at arrow). Postural-reflex deficit (A, Bederson test; normal scoreϭ5), sensorimotor deficit (B, De Ryck test; normal scoreϭ16), and integration of motor responses (C, foot-fault test; normal scoreϭ2), were assessed 17 hours (pretreatment time), 2, 7, 14, and 28 days after 3-vo in vehicle-or anti-MBL-A antibody-treated rats or in sham-operated rats. Data are reported as meanϮSD, nϭ7 per group. Two-way ANOVA for repeated measures followed by Bonferroni post hoc test (A through C): *PϽ0.05, **PϽ0.01, ***PϽ0.001, Ab P2D5 versus vehicle-treated rats at each given time. Structural MRI data analysis of brain volumes (T2w) in ischemic rats treated with vehicle or with anti-MBL-A antibody: total lesion volume (E, measured as the whole T2w hyperintense tissue across brain areas, red ROI in D) and atrophy (measured as residual T2w hypointense tissue) in hippocampus (F, yellow ROI in D) and cortex (G, green ROI in D) for ipsi-and contralateral areas. Asterisks (blue) identify ventricles. Data are reported as scatter-dot plots and mean (bar), nϭ7 per group. Two-way ANOVA for matched values (ipsi-and contralateral sides) followed by Bonferroni post hoc test (F and G) and unpaired t test with a Welch correction (E); *PϽ0.05, **PϽ0.01, ***PϽ0.001, comparisons as indicated by horizontal lines. Ab indicates antibody; MBL, mannose-binding lectin; 3-vo, 3-vessel occlusion model; and ROI, region of interest.
Detailed analysis of the MBL gene in humans has revealed that a surprisingly high percentage of individuals (15%-30% depending on the population considered) carries a genetic deficiency in MBL that leads to low circulating levels of serum MBL. 42 These subjects have not been found to be prone to severe infections in prospective studies; rather, the high diffusion of MBL-low individuals suggests that a relative lack of MBL may be beneficial to the host under certain circumstances. 43 Notably, 2 human studies have recently investigated the role of MBL in stroke and found that a genetic deficiency in MBL is associated with a better outcome after acute stroke in humans, 28, 44 thus further strengthening the hypothesis that inhibition of MBL in the clinical setting of stroke may have significant and beneficial outcomes.
As recently highlighted, 45 MBL has been, up to now, a somewhat forgotten molecule. However, recent data are strongly suggesting an important role for MBL and the lectin pathway in the pathogenesis of brain injury. 12, 28, 44, 46 Our data provide strong support to the concept that MBL inhibition may be a relevant therapeutic target in humans, one with a wide therapeutic window of application. Thus, we propose MBL as a novel therapeutic target for stroke.
